Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (November 2025)
20 slides from Cynata Therapeutics's investor presentation, Nov 17, 2025
Slide 1: ASX Announcement: Updated Investor Presentation
ASX ANNOUNCEMENT 17 November 2025 Updated Investor Presentation Melbourne, Australia; 17 November 2025: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to release an updated investor presentati
Slide 2: A New Standard In Cell Therapy
For personal use only A New Standard In Cell Therapy Investor Presentation – November 2025 (ASX:CYP)
Slide 3: Important Information
Important Information Summary information Forward-looking statements This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (CYP, or This Presentation contains certain ‘forward looking statements’, which can generally be identified by the use of forward
Slide 4: Cynata Therapeutics Front-Runner Status
Cynata Therapeutics Front-Runner Status For personal use only Next-generation Mesenchymal Stromal Cells (MSCs) 1 Commercialising Cymerus , a novel platform producing MSCs World-first: scalable MSCs from a single blood donation - once, at scale from a single blood donation MSCs are powerful immune-mo
Slide 5: Capital Structure
Capital Structure Financial Information For personal use only Share price (14 November 2025) A$0.245 Shares on issue ~237.5m Strong balance sheet. Positioned for upside. Market capitalisation ~A$58m Cash1 ~ A$4.9m Backed by institutions: Fidelity, BioScience Managers, and Fujifilm among top holders
Slide 6: Cynata Is At An Inflection Point
Cynata Is At An Tightly focused clinical pipeline Inflection Point Phase 1 Phase 2 Phase 3 Market Size Next Catalyst* For personal use only Ongoing Osteoarthritis Results: US$11.6bn3 Q2 CY 2026 CYP-004 Entering the most important Acute Graft vs Ongoing chapter in Cynata’s history Results: Host Disea
Slide 7: MSCs: Nature's Repair Cells
For personal use only MSCs: Nature’s What are MSCs? Why They Matter Where They’re Going Repair Naturally found in small Target root causes of many 1,800+ clinical Cells quantities in the body diseases, not just symptoms trials initiated globally Regulate and support Safe and well-tolerated Addressin
Slide 8: Conventional vs Cymerus MSC Manufacturing
Conventional MSC Manufacturing Challenges 1 2 3 4 New donors required on ongoing basis Donor Tissue Cell Culture Batch Sourcing new donors → cost & complexity For personal use only Collection Isolation Expansion Production Donor variability → MSC inconsistency MSCs sourced from MSCs must be Cells gr
Slide 9: ASX Peers
ASX Peers Company1 MSC Type Indications Current Clinical Programs2 For personal use only Marketing Neuroscientific Phase 1 Phase 2 Phase 3 approval Biopharmaceuticals Crohn’s Disease (ASX:NSB) Undertaking Special Access Scheme Donor-derived MSCs program before Phase 2 A$45 million MARKET CAP Cynata
Slide 10: Cell Source Matters
Cell Source Matters Cynata’s iPSC-derived Cymerus MSCs shown to be superior to donor-derived MSCs in multiple important ways For personal use only Independent validation published in Bone marrow/ adipose- Nature’s npj Regenerative Medicine Feature Cynata’s Cymerus MSCs derived MSCs (Feb 2025)1 High
Slide 11: Osteoarthritis
Osteoarthritis Osteoarthritis There’s no cure. Only symptom relief or invasive surgery. For personal use only There’s no cure. Only symptom relief and/or invasive surgery. What is Osteoarthritis? • Chronic joint disease causing pain, stiffness, and reduced mobility • Driven by inflammation and carti
Slide 12: Our Osteoarthritis Product
Our Osteoarthritis Product For personal use only Our Product: CYP - 004 MSC Pilot Trials Phase 3 Trial • World’s largest MSC-based osteoarthritis trial – 321 patients, managed by the University • Single intra-articular injection – • Early phase 3rd party studies with of Sydney, funded by NHMRC minim
Slide 13: Acute Graft vs Host Disease (aGvHD)
Acute Graft vs Host Disease (aGvHD) For personal use only When life-saving transplants become life-threatening. 1 2 3 4 Donor’s bone Donor’s cells Donor’s Immune cells marrow or stem cells view the patient attack patient cells Symptoms can be severe are transplanted body as foreign throughout the bo
Slide 14: Our aGvHD Product
Our aGvHD Product Current Standard of Care for aGvHD Our Product: CYP-001 For personal use only • Delivered via intravenous infusion for >38,000 Bone Marrow Transplants per year systemic immune modulation. Up to 50% patients develop aGvHD1,2 • Aims to reduce reliance on steroids, improve survival, a
Slide 15: Our Phase 2 aGvHD Trial
Our Phase 2 aGvHD Trial For personal use only Phase 2 Overview Phase 2 Endpoints* Regulatory Milestones • Global, randomised, double-blind, • Primary Endpoint: Overall placebo-controlled Phase 2 study Response Rate (ORR) at Day 28 FDA FDA EU EMA Orphan Drug Cleared IMPD • CYP-001 + steroids vs stero
Slide 16: Cynata's Broader Disease Pipeline
Cynata’s Broader Disease Pipeline Current Additional Clinical Programs Strong Pre-Clinical Data For personal use only Respiratory Diseases Immune-Related Disorders Kidney Transplantation (Phase 1/2 – Ongoing) • Cynata’s Phase 1/2 trial underway (Netherlands) with Cymerus MSCs • Investigating reduced
Slide 17: The Next 6-9 Months Will Define Cynata
The Next 6-9 Months Will Define Cynata Upcoming Landmark Readouts Later stage results could become a strategic trigger For personal use only Market Size Next Catalyst* Licensing / Partnering Phase 3 Results: • Positive Phase 2 & 3 results can trigger regional or indication-specific deals Osteoarthri
Slide 18: The Investment Case: Why Cynata? Why Now?
Service One Service Three For personal use only But I must But I must Solves the MSC First mover with no Lead asset backed explain to you explain to you manufacturing direct peers - only by FDA Orphan Drug The how this bottleneck with single- clinical grade iPSC how this and designation donor scalab
Slide 19: Thank You.
For personal use only Thank You. Kilian Kelly, PhD Chief Executive Officer and Managing Director Cynata Therapeutics Limited Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia +61 (03) 7067 6940 investors@cynata.com
Slide 20: Board & Senior Management
Board & Senior Management Highly skilled and experienced senior leadership team Dr Kilian Kelly Dr Geoff Brooke Chief Executive Officer & For personal use only Independent Non-Executive Chair Managing Director • 30+ years' experience in the healthcare • 20+ years' experience in biopharma R&D investm
Cynata Therapeutics — Investor Presentation (November 2025) on 6ix